Citations

Clear

873 citation(s) found for "Carlson, EE".

Rate of Hearing Preservation After Stereotactic Radiosurgery for Treatment of Vestibular Schwannoma: Analysis of Patients With 100% Word Recognition Scores
Vargas, Hernan, Khandalavala, Karl R. , Marinelli, John P. , Lohse, Christine M. , Link, Michael J., Carlson, Matthew L., Link, Michael J. , Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | January 30, 2026 | Volume: 47 | Issue: 4 | Pages: 630-633

10.1097/mao.0000000000004844 | PMID 41612570 Get It

Objective: To evaluate hearing outcomes after treatment with stereotactic radiosurgery (SRS) for sporadic vestibular schwannoma (VS) among patients with baseline 100% word recognition scores (WRS). Study design: Historical cohort. Setting: Tertiary academic medical center. Patients: Patients with 100% WRS on audiometric testing at initial treatment with SRS. Interventions: Gamma Knife SRS. Main outcome measures: Rate of maintaining serviceable hearing (SH), defined as American Academy of Otolaryngology-Head and Neck Surgery hearing class A or B. Results: In total, 125 patients had 100% WRS at SRS for sporadic VS. Median age at SRS was 56 years (IQR: 51 to 62) and median pure tone average (PTA) at SRS was 20 dB HL (IQR: 13 to 31). Sixty-eight patients progressed to non-SH at a median of 3.4 years after SRS (IQR: 1.0 to 8.6); the median duration of follow-up for the 57 patients who maintained SH was 5.1 years (IQR: 2.8 to 9.6). Rates of maintaining SH (95% CI, number still at risk) at 1, 3, 5, 7, and 10 years after SRS were 88% (82 to 94, 101), 75% (68 to 84, 81), 61% (53 to 71, 55), 58% (49 to 68, 43), and 44% (35 to 56, 26), respectively. Each 10-dB HL increase in PTA at SRS was associated with a 52% increased risk of progression to non-SH (hazard ratio: 1.52, 95% CI: 1.24-1.87, P <0.001). Conclusions: Despite having 100% pretreatment WRS, most patients with sporadic VS treated with SRS experienced clinically significant hearing decline over time. Even among this cohort of patients with excellent baseline hearing, at 10 years after treatment, only 44% of patients maintained SH.
Improving a Plasma Biomarker Panel for Early Detection of Pancreatic Ductal Adenocarcinoma with Aminopeptidase N (ANPEP) and Polymeric Immunoglobulin Receptor (PIGR)
Krusen, Brianna M. , Gimotty, Phyllis, Donahue, Greg , Till, Jacob E. , Yin, Melinda , Carlson, Erin E. , Bamlet, William R. , Carpenter, Erica L. , Majumder, Shounak, Oberg, Ann L. , Zaret, Kenneth S. , Majumder, Shounak , Gimotty, Phyllis A , Majumder, Shounak , Bamlet, William R , Krusen, Brianna M , Carlson, Erin E. , Carpenter, Erica L. , Zaret, Kenneth S.

Mayo Clinic

Clinical Cancer Research | January 28, 2026 | Volume: 32 | Issue: 4 | Pages: 756-769

10.1158/1078-0432.ccr-25-3297 | PMID 41593855 Get It

Abstract Purpose: Pancreatic ductal adenocarcinoma (PDAC) is typically detected too late for useful therapeutic interventions; hence, we sought blood biomarkers to detect early-stage disease. Experimental Design: Using mass spectrometry and ELISA on plasma pools from the University of Pennsylvania (Penn) and the Mayo Clinic (Mayo), we identified aminopeptidase N (ANPEP) and polymeric immunoglobulin receptor (PIGR) as increased in early-stage (stage I/II) PDAC plasma compared with controls. We tested ANPEP and PIGR, along with prior data for thrombospondin 2 (THBS2) and carbohydrate antigen 19-9 (CA19-9), in retrospective phase II studies using separate cohorts of PDAC plasmas at different stages versus healthy or nonmalignant disease controls (DC) from Penn (n = 135) and Mayo (n = 537). Results: Comparing healthy controls with stage I/II PDAC, we obtained area under the receiver-operating characteristic curves (AUC) of 0.78 [95% confidence interval (CI), 0.68–0.86]/0.80 (95% CI, 0.74–0.85; ANPEP) and 0.81 (95% CI, 0.70–0.88)/0.86 (95% CI, 0.82–0.90; PIGR) for the Penn/Mayo phase II studies, respectively. In multivariable models, CA19-9/THBS2/ANPEP, CA19-9/THBS2/PIGR, and CA19-9/THBS2/ANPEP/PIGR elicited AUC of 0.94 to 0.96 for Penn and 0.97 for Mayo. Notably, the four-marker panel elicited AUC of 0.87 for the Mayo stage I/II versus DC and 0.91 for stages I to IV versus DC. At a specificity of 95%, a plasma biomarker panel composed of CA19-9 (≥35 U/mL), THBS2 (≥42 ng/mL), ANPEP (≥2,995 ng/mL), and PIGR (≥1,800 ng/mL) yielded a sensitivity of 91.9% for PDAC stages I to IV and 87.5% for PDAC stage I/II. Conclusions: Adding ANPEP and PIGR to a plasma biomarker panel of CA19-9 and THBS2 enhances the detection of early-stage PDAC when comparing cancer versus healthy or nonmalignant DC. Given the concordance of our data in two retrospective phase II studies, assessments in prediagnostic cases are warranted.
Minimal important differences to assess cross-sectional differences among groups and minimal important changes to assess longitudinal within-patient changes for the Mayo Clinic Vestibular Schwannoma Quality of Life Index
Carlson, Matthew L., Lohse, Christine M., Tombers, Nicole M. , Mj, Link, Yost, K. , Carlson, Matthew, Lohse, Christine M. , Link, Michael J. , Yost, Kathleen J.

Mayo Clinic

Journal of Neurosurgery | January 24, 2026 | Volume: 144 | Issue: 4 | Pages: 972-978

10.3171/2025.9.jns251249 | PMID 41576374 Get It

OBJECTIVE The minimal important difference (MID) and minimal important change (MIC) are two metrics that bridge the gap between statistical significance and clinical relevance and are critical to managing clinical decisions and conducting clinical research. The objective of this study was to define MIDs to evaluate cross-sectional differences among groups and to define MICs to evaluate longitudinal within-patient changes for the Mayo Clinic Vestibular Schwannoma Quality of Life (VSQOL) Index. METHODS Anchor-based methods were used to define MIDs and MICs for the VSQOL Index domain scores, which range from 0 to 100 points, for a national cohort of 1050 patients with sporadic vestibular schwannoma, 644 of whom completed the VSQOL Index twice approximately 1 year apart. RESULTS The median of the MID estimates for the VSQOL Index domains were: hearing problems (17, IQR 12.5–21); dizziness and imbalance (21, IQR 18–23); pain, discomfort, and tinnitus (19.5, IQR 15–23.5); problems with face or eyes (18, IQR 17–28); impact on physical, emotional, and social well-being (19.5, IQR 14.5–23.5); difficulty with thinking and memory (23.5, IQR 18.5–28.5); global quality of life (12, IQR 8–16); and satisfaction or regret (13.5, IQR 7–17). MIC estimates for the hearing problems and satisfaction and regret domains were not obtained because the correlations between these domain scores and their associated anchors were not sufficiently strong. The MIC estimates (minimum and maximum) for the remaining domains were: dizziness and imbalance (7.2 and 8.3); pain, discomfort, and tinnitus (8.3 and 8.5); problems with face or eyes (7.0 and 7.4); impact on physical, emotional, and social well-being (2.1 and 8.0); and difficulty with thinking and memory (12.9 and 15.0). The median of the MIC estimates for global quality of life was 5.2 (IQR 3.7–5.6). CONCLUSIONS The MIDs and MICs reported herein provide a framework to interpret quality-of-life benefit or harm cross-sectionally among groups and longitudinally within patients. Moving forward, these values should be considered when interpreting studies using the VSQOL Index to assess disease-specific quality of life in patients with sporadic vestibular schwannoma.
Multiomics-driven discovery of predictive biomarkers and strategies to overcome resistance to SFK-YAP inhibition in cholangiocarcinoma
Kuipers, Hendrien , Carlson, Danielle M. , Jessen, Erik , Abeynayake, Aushinie, Mun, Dong-Gi, Tomlinson, Jennifer L. , Abdelrahman, Amro M. , Werneburg, Nathan W., Li, B. , Ozmert, Enis H., Conboy, Caitlin B. , Truty, MD Mark, Pandey, Akhilesh, Ilyas, Sumera, Gores, Gregory J., Smoot, Rory L., Mun, Dong‐Gi , Mun, Dong-Gi , Tomlinson, Jennifer , Abdelrahman, Amro M , Borad, Mitesh J , Truty, Mark J , Ilyas, Sumera Irie , Gores, Gregory J. , Smoot, Rory L , Jessen, Erik , Conboy, Caitlin B , Carlson, Danielle Marie , Sample, Jack W. , Borad, Mitesh J. , Truty, Mark J. , Ilyas, Sumera I. , Gores, Gregory J.

Mayo Clinic

No container title available | January 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.21.699926 | PMID 41648234 Get It

ABSTRACT The limited efficacy of current therapies against cholangiocarcinoma (CCA) necessitates the development of novel treatment strategies. Src family kinases (SFKs) contribute significantly to tumor progression and resistance in CCA. Therefore, we investigated the novel, first-in-class SFK ‘OFF’ inhibitor NXP900 in diverse preclinical CCA models, including those with acquired resistance. This study evaluated the therapeutic effects of NXP900 and detailed adaptive molecular responses to SFK inhibitor therapy. We also aimed to identify biomarkers predictive of drug sensitivity using integrated multiomic profiling and develop strategies to overcome resistance. NXP900 inhibited YAP activity through direct inhibition of tyrosine phosphorylation and indirect activation of the Hippo pathway via LATS. These effects were associated with decreased tumor cell viability in CCA cell lines and several in vivo models. Notably, IDH -mutant patient-derived xenograft CCA models were particularly sensitive to NXP900. NXP900 also synergized with gemcitabine/cisplatin chemotherapy, enhancing antitumor efficacy in both in vitro and in vivo models. Multiomic analyses combining transcriptomics, global proteomics, and phosphoproteomics identified molecular features associated with primary response and acquired resistance. IL13RA-AKT signaling was upregulated in resistant models; NXP900 sensitivity could be restored with AKT or IL13RA2 inhibition. Together, these findings demonstrate the therapeutic potential of NXP900 as a novel YAP inhibitor in CCA and support further investigation in a clinical trial. Graphical Abstract
Long-term tumor control after Gamma Knife radiosurgery for sporadic vestibular schwannoma
Marinelli, John P. , Daher, Ghazal S. , Khandalavala, Karl R. , Babajanian, Eric E. , Dornhoffer, James R. , Lohse, Christine M., Pollock, Bruce E., Brown, Paul D., Gompel, Jamie J. Van, Celda, María Peris, Neff, Brian A., Driscoll, Colin L. W., Carlson, Matthew L. , Link, Michael J., Lohse, Christine M. , Pollock, Bruce E. , Gompel, Jamie J. Van , Link, Michael J.

Mayo Clinic

Journal of Neurosurgery | January 22, 2026 | Volume: 144 | Issue: 4 | Pages: 965-971

10.3171/2025.8.jns25829 | PMID 41569741 Get It

OBJECTIVE The objective of this study was to describe the long-term efficacy of single-fraction stereotactic radiosurgery (SRS) for the primary treatment of sporadic vestibular schwannoma. METHODS Adult (≥ 18 years of age) patients with sporadic vestibular schwannoma who underwent SRS from 2000 through 2022 were included. RESULTS A total of 749 patients met inclusion criteria, the majority (n = 566, 76%) of whom had tumors extending into the cerebellopontine angle at SRS. The median patient age at SRS was 62 years, half (50%) of the patients were women, and 744 (99%) exhibited House-Brackmann grade I facial nerve function at SRS. A total of 42 patients experienced radiosurgical failure and underwent salvage treatment; the median duration of follow-up for the patients who did not undergo salvage treatment was 7.0 years. Overall tumor control rates (95% CI, number still at risk) at 1, 3, 5, 10, and 15 years after SRS were 100% (100%–100%, 718), 98% (97%–99%, 589), 96% (94%–97%, 464), 92% (90%–95%, 258), and 91% (89%–94%, 125), respectively. Patient age (hazard ratio [HR] for a 10-year increase of 0.92, 95% CI 0.71–1.19; p = 0.5), presence of a macrocystic tumor (HR 0.59, 95% CI 0.14–2.46; p = 0.5), and treated tumor volume (HR for a 1-cm 3 increase of 1.02, 95% CI 0.88–1.18; p = 0.8) were not significantly associated with the risk of salvage. Three distinct post-SRS tumor behavior patterns were observed, with 13% of patients demonstrating tumor pseudoprogression, all but 4 of whom demonstrated pseudoprogression by year 5 post-SRS. CONCLUSIONS SRS demonstrates durable tumor control through 15 years of follow-up in most patients (91%); however, a minority are found to still experience SRS failure even beyond 10 years of surveillance. Although occurring in only a minority of patients, tumor pseudoprogression can be evident out to 5 years or longer post-SRS.
Defining clinically significant tumor size in sporadic vestibular schwannoma to inform timing of radiosurgery during wait-and-scan management: further evidence supporting size threshold surveillance
Carlson, Matthew L. , Marinelli, John P. , Babajanian, Eric E. , Daher, Ghazal S. , Dornhoffer, James R. , Khandalavala, Karl R. , Lohse, Christine M., Gompel, Jamie J. Van, Celda, María Peris, Neff, Brian A., Driscoll, Colin L. W., Link, Michael J., Lohse, Christine M. , Gompel, Jamie J. Van , Link, Michael J.

Mayo Clinic

Journal of Neurosurgery | January 22, 2026 | Volume: 144 | Issue: 4 | Pages: 955-964

10.3171/2025.8.jns25830 | PMID 41569717 Get It

OBJECTIVE Wait-and-scan surveillance is now commonly employed for initial management of small- and medium-sized vestibular schwannomas. Although small differences in tumor size are unlikely to impact outcomes significantly, treatment with either radiosurgery or microsurgery is usually recommended following radiological detection of tumor growth. The objective of the current study was to identify potential inflection points in vestibular schwannoma tumor size, where the risks of treatment with single-fraction stereotactic radiosurgery (SRS) accelerate to inform timing of intervention. METHODS Adult (≥ 18 years old) patients with sporadic vestibular schwannoma who underwent SRS from 2000 through 2022 were included. RESULTS A total of 749 patients with a median age at SRS of 62 years were studied, the majority (n = 566 [76%]) of whom had tumors extending into the cerebellopontine angle (CPA) at SRS. The optimal tumor size cut point to predict SRS failure and need for salvage treatment was 4 mm or more of CPA extension (c-index 0.59, HR 3.60, p = 0.01). The optimal tumor size cut point to predict the outcome of facial nerve paresis was 13 mm or more of CPA extension, resulting in a c-index of 0.63 (HR 2.88, p = 0.01). Among patients with at least 3 months of surveillance before SRS, those with a tumor growth rate ≥ 2.5 mm/year were more likely to undergo salvage treatment than those with a growth rate < 2.5 mm/year, although this difference did not achieve statistical significance (HR 1.82, p = 0.18). CONCLUSIONS The risk of SRS failure requiring salvage treatment and the risk of post-SRS facial nerve paralysis increase at sizes of approximately 4 and 13 mm extension into the CPA, respectively, providing a size threshold anchor to help guide treatment decision-making regarding timing of SRS. Furthermore, rapid tumor growth during the initial wait-and-scan period may be associated with an increased risk of radiosurgical failure, which may influence choice of treatment.
Prescription Patterns and Outcomes of Topical Antibiotic Irrigations in Difficult-to-Treat Chronic Rhinosinusitis
Valencia-Sanchez, Bastien A., Jabbour, Christopher , Wilson, Penny , Najmi, Natasha N. , Alhalabi, Alaa , Squire, Jacqueline D. , Stokken, Janalee, Donaldson, Angela M. , Stokken, Janalee K. , Valencia, Bastien A. , Valencia‐Sanchez, Bastien A. , Wilson, Prishae , Najmi, Natasha, Squire, Jacqueline, Carlson, Matthew L , Squire, Jacqueline

Mayo Clinic

American Journal of Rhinology & Allergy | January 19, 2026 | Volume: 40 | Issue: 3 | Pages: 230-238

10.1177/19458924251413671 | PMID 41553831 Get It

Background A substantial proportion of patients with chronic rhinosinusitis (CRS) remain partly controlled or uncontrolled despite endoscopic sinus surgery (ESS) and maximal medical therapy. For these difficult-to-treat cases, topical antibiotic irrigations have been proposed as an adjunctive therapy, particularly when delivered via large-volume, low-pressure systems that enhance sinus penetration post-ESS. Evidence on their efficacy and prescribing patterns in this population remains limited. Objective This study aims to evaluate the use and outcomes of topical antibiotic irrigations in patients with difficult-to-treat CRS. Methods A retrospective, multi-site cohort study was conducted across tertiary academic medical centers. Adult patients with persistent CRS symptoms despite bilateral full-house ESS and conventional postoperative medical management were included. Patients with cystic fibrosis or granulomatosis with polyangiitis were excluded. Demographic, clinical, and treatment data were collected. Primary outcomes were infection resolution at 8 weeks and changes in Sino-Nasal Outcome Test-22 (SNOT-22) scores. Results Sixty-seven patients met inclusion criteria. Mupirocin (41.8%), tobramycin (23.9%), and gentamicin (17.9%) were the most commonly prescribed agents. After 8 weeks, 62.7% of patients achieved infection clearance. Among 44 patients with SNOT-22 data, scores improved significantly from 34.8 ± 20.2 to 21.8 ± 14.7 ( P < .001). Improvement in SNOT-22 scores was more pronounced in patients who cleared the infection compared to those who did not. Conclusion Large-volume topical antibiotic irrigations were associated with high infection resolution rates and clinically meaningful SNOT-22 improvements in patients with difficult-to-treat CRS. These findings support their potential utility as an adjunctive therapy in select postsurgical patients and warrant further prospective investigation.
Association of Radiologic Findings of Otosclerosis Using Photon-Counting Computed Tomography With Hearing
Babajanian, Eric E. , Swartz, Hayden J., Leng, Shuai, Lohse, Christine M. , Lane, Jack I., Carlson, Matthew L., Benson, John C. , Farnsworth, Paul J. , Swartz, Hayden J., Leng, Shuai , Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | December 23, 2025 | Volume: 47 | Issue: 3 | Pages: 418-422

10.1097/mao.0000000000004798 | PMID 41432388 Get It

Objective: To examine the association of extent of otosclerotic plaque using high-resolution photon-counting computed tomography (PCCT) with hearing and surgical outcomes. Study design: Historical cohort. Setting: Large academic center. Patients: Patients with otosclerosis who completed PCCT imaging at time of initial evaluation. Interventions: Observation, surgery. Main outcome measures: Audiometric data. Results: A total of 53 ears were eligible for study. The mean age at PCCT was 51 years (SD: 14). The mean extent of oval window otosclerotic plaque measured in radial degrees was 112 (SD: 65) and the mean otosclerotic depth was 1.6mm (SD: 0.6). The mean air-bone gap pure-tone average was 18 dB (SD: 12) and the mean Carhart degree was 9 dB (SD: 10). The radial degrees of oval window extent were not significantly associated with air-bone gap (correlation coefficient: 0.14; P =0.3) or Carhart degree (correlation coefficient: 0.04; P =0.8). Likewise, otosclerotic plaque depth was not significantly associated with air-bone gap (correlation coefficient: −0.19; P =0.2) or Carhart degree (correlation coefficient: −0.08; P =0.6). After PCCT, 22 ears underwent surgery. In this subset, oval window extent and plaque depth were not significantly associated with the postoperative changes in air-bone gap or high-frequency thresholds. Conclusions: Despite enhanced visualization of subtle abnormalities with PCCT imaging, the extent of oval window otosclerotic plaque, measured in angular degrees and depth, was not associated with hearing loss at time of initial evaluation or postoperative audiologic changes in patients with otosclerosis.
Vestibular and Audiometric Outcomes in Cochlear Implantation With Simultaneous Endolymphatic Sac Decompression for Patients With Ménière Disease
Khandalavala, Karl R. , Babajanian, Eric E. , Marinelli, John P. , Lohse, Christine M. , Driscoll, C W, Carlson, Matthew L., Neff, Brian A., Dornhoffer, James R. , Olson, Brennan G, Driscoll, Colin L., Olson, Brennan , Driscoll, Colin L. W., Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | December 23, 2025 | Volume: 47 | Issue: 3 | Pages: 475-478

10.1097/mao.0000000000004788 | PMID 41432410 Get It

Objective: To evaluate the impact of cochlear implantation (CI) and simultaneous endolymphatic sac decompression (ELSD) on vestibular and audiometric outcomes in patients with advanced Ménière disease (MD). Study design: Historical cohort. Setting: Tertiary academic medical center. Patients: Patients with medically refractory MD who underwent CI with or without simultaneous ELSD from 2000 through 2024. Interventions: CI with or without ELSD. Main outcome measures: Post-CI patient-reported changes in vertigo severity and frequency, Consonant-Nucleus-Consonant word (CNCw) scores, and AzBio sentences in quiet scores. Results: Ninety-nine patients with preoperative vertigo secondary to MD were eligible for study, including 17 (17%) who underwent simultaneous ELSD. In total, 15 (88%) and 2 (12%) of the 17 patients with simultaneous ELSD reported improvement and stability in vertigo severity, respectively; in comparison, 26 (32%), 40 (49%), and 16 (20%) of the 82 patients with CI alone reported improvement, stability, and worsening in vertigo severity, respectively ( P <0.001). Likewise, 15 (88%) and 2 (12%) of the patients with simultaneous ELSD reported improvement and stability in vertigo frequency, respectively, whereas 21 (26%), 43 (52%), and 18 (22%) of patients with CI alone reported improvement, stability, and worsening in vertigo frequency, respectively ( P <0.001). Post-CI speech recognition scores were not significantly different between the simultaneous ELSD and CI alone groups [median (IQR) CNCw 70 (38 to 82) vs. 72 (58 to 82) and median (IQR) AzBio quiet 87 (67 to 96) vs. 87 (73 to 94), respectively]. Conclusions: In patients with MD, CI with simultaneous ELSD provides improvement in vertigo symptoms and similar audiometric outcomes when compared with CI alone. In appropriately selected patients with both refractory vestibular symptoms and sensorineural hearing loss meeting criteria for implantation, CI with simultaneous ELSD offers improvement in severity and frequency of vertigo as well as successful auditory rehabilitation.
Proposed Development of a New Staging System for Hearing Loss: Countermeasure 2 of the Hearing Health Collaborative
Carlson, Matthew L., Zwolan, Teresa A. , Cosetti, Maura K. , Gubbels, Samuel P., Hashmi, Ardeshir Z. , Holcomb, Meredith A. , Jilla, Anna Maria, Kelley, Barbara, Lohse, Christine M. , Marinelli, John P. , McKee, Michael , Moody-Antonio, Stephanie A., Miller, Erin L. , Nassiri, Ashley M. , Reed, Nicholas S. , Spankovich, Christopher , Tieben, John, Zeitler, Daniel M. , Sydlowski, Sarah A., Tieben, John E, Carlson, Matthew L. , Bush, Matthew L. , Dunn, Camille C. , Gurgel, Richard Klaus , Hunter, Jacob B. , Jilla, Anna Marie , Moody‐Antonio, Stephanie , Miller, Erin L., Sladen, Douglas P. , Yueh, Bevan , Sydlowski, Sarah

Mayo Clinic

Otology & Neurotology | December 22, 2025 | Volume: 47 | Issue: 2 | Pages: e158-e163

10.1097/mao.0000000000004700 | PMID 41428499 Get It

Hearing loss is a highly prevalent disease state affecting almost 1 in 5 individuals globally. Growing research shows that untreated or undertreated hearing loss carries significant long-term sequelae, including increased risk of social isolation, depression, and cognitive decline, among other ramifications. Limited awareness and common misperceptions among the general US adult population and primary care providers contribute to low rates of referral to hearing specialty clinics and underutilization of hearing aids, cochlear implants, and other rehabilitative devices. Comprised of diverse membership, the Hearing Health Collaborative (HHC) was formed in May 2021 to identify and overcome challenges impacting good health care practices and public policy on hearing care in connection with healthy aging. This editorial documents a recent outcome of the HHC derived from a structured A3 process. Specifically, initiative 2, a proposal to develop a simple, clinically anchored staging system primarily for use by frontline providers and patients, is presented. Unlike other common disorders that harbor long-term health sequelae, a corresponding pragmatic clinical staging system—leveraging precedent disease staging convention, based on clinically meaningful outcomes and prognosis for acquired hearing loss—does not exist. The development of this staging system will potentially allow for improved communication across providers and patients, facilitate referral pathways, and ultimately enable patient access to timely and appropriate care.